1 Sacco RL，Chong JY，Prabhakaran S，et al.

Experimental treatments for acute ischemic stroke[J].

Lancet，2007，369：331-341.

2 Matthew D. Hammond，Youxi Ai，et al. Gr1+

macrophages and dendritic cells dominate the

inflammatory infiltrate 12 h after experimental

intracerebral hemorrhage[J]. Transl Stroke Res，2012，

3：125-131.

3 Emsley HC，Hopkins SJ. Post-stroke immunodepression

and infection：an emerging concept[J]. Infect

Disord Drug Targets，2010，10：91-97.

4 Fathali N，Ostrowski RP，Hasegawa Y，et al. Splenic

immune cells in experimental neonatal hypoxiaischemia[

J]. Transl Stroke Res，2013，4：208-219.

5 Picascia A，Grimaldi V，Iannone C，et al. Innate

and adaptive immune response in stroke：Focus on

epigenetic regulation[J]. J Neuroimmunol，2015，289：

111-120.

6 Chaturvedi M，Kaczmarek L. MMP-9 inhibition：a

therapeutic strategy in ischemic stroke[J]. Mol

Neurobiol，2014，49：563-573.

7 Famakin BM，Mou Y，Johnson K，et al. A new

role for downstream Toll-like receptor signaling in

mediating immediate early gene expression during

focal cerebral ischemia[J]. J Cereb Blood Flow Metab，

2014，34：258-267.

8 Fadakar K，Dadkhahfar S，Esmaeili A，et al. The

role of Toll-like receptors (TLRs) in stroke[J]. Rev

Neurosci，2014，25：699-712.

9 Iadecola C，Anrather J. The immunology of stroke：

from mechanisms to translation[J]. Nat Med，2011，17：

796-808.

10 Chamorro A，Meisel A，Planas AM，et al. The

immunology of acute stroke[J]. Nat Rev Neurol，2012，

8：401-410.

11 Yilmaz G，Arumugam TV，Stokes KY，et al. Role

of T lymphocytes and interferon-gamma in ischemic

stroke[J]. Circulation，2006，113：2105-2112.

12 Planas AM，Gomez-Choco M，Urra X，et al. Brainderived

antigens in lymphoid tissue of patients with

acute stroke[J]. J Immunol，2012，188：2156-2163.

13 Kamel H，Iadecola C. Brain-immune interactions and

ischemic stroke：clinical implications[J]. Arch Neurol，

2012，69：576-581.

14 Ziv Y，Ron N，Butovsky O，et al. Immune cells

contribute to the maintenance of neurogenesis

and spatial learning abilities in adulthood[J]. Nat

Neurosci，2006，9：268-275.

15 Gelderblom M，Leypoldt F，Steinbach K，et al.

Temporal and spatial dynamics of cerebral immune

cell accumulation in stroke[J]. Stroke，2009，40：

1849-1857.

16 Stubbe T，Ebner F，Richter D，et al. Regulatory T

cells accumulate and proliferate in the ischemic

hemisphere for up to 30 days after MCAO[J]. J Cereb

Blood Flow Metab，2013，33：37-47.

17 Brea D，Agulla J，Rodriguez-Yanez M，et al.

Regulatory T cells modulate inflammation and reduce

infarct volume in experimental brain ischaemia[J]. J

Cell Mol Med，2014，18：1571-1579.

18 Na SY，Mracsko E，Liesz A，et al. Amplification of

regulatory T cells using a CD28 superagonist reduces

brain damage after ischemic stroke in mice[J]. Stroke，

2015，46：212-220.

19 Meisel C，Schwab JM，Prass K，et al. Central

nervous system injury-induced immune deficiency

syndrome[J]. Nat Rev Neurosci，2005，6：775-786.

20 Gill D，Veltkamp R. Dynamics of T cell responses after

stroke[J]. Curr Opin Pharmacol，2016，26：26-32.

21 Famakin BM. The immune response to acute

focal cerebral ischemia and associated post-stroke

immunodepression：a focused review[J]. Aging Dis，

2014，5：307-326.

22 Liesz A，Zhou W，Mracsko E，et al. Inhibition of

lymphocyte trafficking shields the brain against

deleterious neuroinflammation after stroke[J]. Brain，

2011，134：704-720.

23 Zierath D，Thullbery M，Hadwin J，et al. CNS

immune responses following experimental stroke[J].

Neurocrit Care，2010，12：274-284.

24 Vargas M，Horcajada JP，Obach V，et al. Clinical

consequences of infection in patients with acute stroke：

is it prime time for further antibiotic trials?[J]. Stroke，

2006，37：461-465.

25 Weidenfeld J，Leker RR，Gai N，et al. The function of

the adrenocortical axis in permanent middle cerebral

artery occlusion：effect of glucocorticoids on the

neurological outcome[J]. Brain Res，2011，1407：90-96.

26 Marklund N，Peltonen M，Nilsson TK，et al. Low and

high circulating cortisol levels predict mortality and

cognitive dysfunction early after stroke[J]. J Intern

Med，2004，256：15-21.

27 Vogelgesang A，Grunwald U，Langner S，et al.

Analysis of lymphocyte subsets in patients with stroke

and their influence on infection after stroke[J]. Stroke，

2008，39：237-241.

28 Urra X，Cervera A，Villamor N，et al. Harms and

benefits of lymphocyte subpopulations in patients with

acute stroke[J]. Neuroscience，2009，158：1174-1183.

29 Shim R，Wong CH. Ischemia，immunosuppression

and infection--tackling the predicaments of poststroke

complications[J]. Int J Mol Sci，2016，17.

30 Thangada S，Khanna KM，Blaho VA，et al. Cellsurface

residence of sphingosine 1-phosphate receptor

1 on lymphocytes determines lymphocyte egress

kinetics[J]. J Exp Med，2010，207：1475-1483.

31 Hunter SF，Bowen JD，Reder AT. The direct

effects of fingolimod in the central nervous system：

implications for relapsing multiple sclerosis[J]. CNS

Drugs，2016，30：135-147.

32 Kraft P，Göb E，Schuhmann MK，et al. FTY720

ameliorates acute ischemic stroke in mice by

reducing thrombo-inflammation but not by direct

neuroprotection[J]. Stroke，2013，44：3202-3210.

33 Czech B，Pfeilschifter W，Mazaheri-Omrani N，et

al. The immunomodulatory sphingosine 1-phosphate

analog FTY720 reduces lesion size and improves

neurological outcome in a mouse model of cerebral

ischemia[J]. Biochem Biophys Res Commun，2009，

389：251-256.

34 Wei Y，Yemisci M，Kim HH，et al. Fingolimod

provides long-term protection in rodent models of

cerebral ischemia[J]. Ann Neurol，2011，69：119-129.

35 Spampinato SF，Obermeier B，Cotleur A，et al.

Sphingosine 1 phosphate at the blood brain barrier：

can the modulation of S1P receptor 1 influence

the response of endothelial cells and astrocytes

to inflammatory stimuli?[J]. PLoS One，2015，10：

e0133392.

36 Kleinschnitz C，Kraft P，Dreykluft A，et al.

Regulatory T cells are strong promoters of acute

ischemic stroke in mice by inducing dysfunction of

the cerebral microvasculature[J]. Blood，2013，121：

679-691.

37 Prager B，Spampinato SF，Ransohoff RM.

Sphingosine 1-phosphate signaling at the blood-brain

barrier[J]. Trends Mol Med，2015，21：354-363.

38 Hasegawa Y，Suzuki H，Sozen T，et al. Activation

of sphingosine 1-phosphate receptor-1 by FTY720

is neuroprotective after ischemic stroke in rats[J].

Stroke，2010，41：368-374.

39 Liu J1，Zhang C，Tao W，Liu M. Systematic review

and meta-analysis of the efficacy of sphingosine-1-

phosphate (S1P) receptor agonist FTY720 (fingolimod)

in animal models of stroke[J]. Int J Neurosci，2013，

123：163-169.

40 Fu Y，Zhang N，Ren L，et al. Impact of an immune

modulator fingolimod on acute ischemic stroke[J].

Proc Natl Acad Sci，2014，111：18 315-18 320.

41 Aoki T，Sumii T，Mori T，et al. Blood-brain barrier

disruption and matrix metalloproteinase-9 expression

during reperfusion injury：mechanical versus embolic

focal ischemia in spontaneously hypertensive rats[J].

Stroke，2002，33：2711-2717.

42 Cai A，Schlunk F，Bohmann F，et al. Coadministration

of FTY720 and rt-PA in an experimental model

of large hemispheric stroke-no influence on functional

outcome and blood-brain barrier disruption[J]. Exp

Transl Stroke Med，2013，5：11.

43 Campos F，Qin T，Castillo J，et al. Fingolimod reduces

hemorrhagic transformation associated with delayed

tissue plasminogen activator treatment in a mouse

thromboembolic model[J]. Stroke，2013，44：505-511.

44 Zhu Z，Fu Y，Tian D，et al. Combination of the

immune modulator fingolimod with alteplase in acute

ischemic stroke：a pilot trial[J]. Circulation，2015，132：

1104-1112.

45 Kawashima S，Yamashita T，Miwa Y，et al. HMGCoA

reductase inhibitor has protective effects

against stroke events in stroke-prone spontaneously

hypertensive rats[J]. Stroke，2003，34：157-163.

46 Chen J，Zhang ZG，Li Y，et al. Statins induce

angiogenesis，neurogenesis，and synaptogenesis after

stroke[J]. Ann Neurol，2003，53：743-751.

47 Szczepanska-Szerej A，Kurzepa J，Wojczal J，et

al. Simvastatin-induced prevention of the increase

in TNF-alpha level in the acute phase of ischemic

stroke[J]. Pharmacol Rep，2007，59：94-97.

48 Baryan HK，Allan SM，Vail A，et al. Systematic

review and meta-analysis of the efficacy of statins in

experimental stroke[J]. Int J Stroke，2012，7：150-156.

49 Smith CJ，Denes A，Tyrrell PJ，et al. Phase II antiinflammatory

and immune-modulating drugs for

acute ischaemic stroke[J]. Expert Opin Investig

Drugs，2015，24：623-643.

50 Ridker PM，Danielson E，Fonseca FA，et al.

Rosuvastatin to prevent vascular events in men and

women with elevated C-reactive protein[J]. N Engl J

Med，2008，359：2195-207.